Arcomas röntgensystem säljs i Nordamerika av Canons dotterbolag Virtual Imaging under produktnamnen RadPro Omnera 400A och 400T. Förutom genom Virtual Imagings egen organisation och distributörer kommer nu dessa produkter även kunna säljas av Canon Medical Systems USAs betydligt större organisation som förvärvades från Toshiba 2017. Detta  innebär en möjligt ökad marknadspenetration i Nordamerika för Arcomas produkter.

Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the first patient has received the first dose in a Phase II clinical trial for Gaucher disease.

Anders Hinsby, Chief Executive Officer, said: “With the enrollment of the first patient in the Gaucher disease trial, we reach another important milestone in the development of our pipeline this year. Glucocerebrosidase deficiency leads to severe neurological manifestations in many patients with Gaucher disease. With this trial we move a step closer to a treatment option for these patients.”

Arcoma har fått en ramorder värd 38 MSEK från amerikanska Virtual Imaging. Leveranser kommer att ske under kommande 12 månader, och planeras bidra till omsättningen med ca 3,5 MSEK under Q2 2018 och med minst 3 MSEK under Q3 2018. Virtual Imaging ägs av Canon och säljer Arcomas röntgensystem både via distributörer och direkt till slutkund i USA och Kanada.

Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products. The equity injection of SEK 60 million will be used to advance the development of Ascelia Pharma’s drug candidates – Mangoral® and Oncoral.

“I am highly satisfied with the support from both current and new shareholders and their confidence in Ascelia Pharma and our promising drug candidates. The funding will enable us to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumordirected immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced the presentation of new preclinical data supporting ALG.APV-527 as a promising new immunotherapeutic candidate for the treatment of a variety of 5T4-expressing solid tumors.

ALG.APV-527 is designed to simultaneously target 5T4 and the co-stimulatory receptor 4-1BB (CD137) to promote potent, tumor-directed immune T-cell activation. 5T4 is a well-defined tumor antigen expressed on many different types of malignancies including, non-small cell lung, renal, pancreas, prostate, breast, colorectal, gastric, ovarian and cervical cancers. Conversely, 5T4 has limited expression on normal tissues, making it an attractive target for cancer immunotherapy.